The Law Offices of Frank R. Cruz Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On October 10, 2023, Akero announced the results of its Phase 2b SYMMETRY trial, revealing that the study had failed to meet its primary endpoint. On this news, Akero’s stock price fell $30.39, or 62.6%, to close at $18.15 per share on October 10, 2023, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Akero securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 at 310-914-5007, by email to [e-mail], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240502991178/en/

The Akero Therapeutics Stock at the time of publication of the news with a fall of -1,25 % to 19,83EUR on Nasdaq stock exchange (02. Mai 2024, 20:33 Uhr).